Abbexa's TP53 Was Successfully Independently Validated
Posted on 2026-11-11
The opportunity cost of an underperforming research reagent can be vast. Quality research starts by purchasing reliable, validated reagents you can trust to perform in the applications you need. That’s why Abbexa are proud to be working with YCharOS, a globally recognised non-profit pushing an open science initiative through the systematic and independent evaluation of commercial research antibodies. YCharOS are playing a key role in tackling the challenge of finding reliable antibodies faced by thousands of researchers worldwide. Recently, our TP53 antibodies abx159710 were validated after being tested in a variety of research applications, including IF, IHC, WB and IP.
TP53 is a common cancer biomarker, as it is the most frequently mutated gene across human cancers. Characterizing this protein can help researchers gauge tumour aggressiveness and prognosis. When a cell’s DNA gets damaged, p53 co-ordinates repair and helps to repair the cell; if the damage is irreversible, then it will initiate apoptosis (programmed cell death). These functions underly its nature as an essential and tireless tumour suppressor, which cancer must alter to survive and spread.
Why do researchers use a TP53 antibody?
As a scientist studying cancer, it is important to be able to understand the processes inside cancerous cells. This antibody allows researchers to visualise the characteristics, quantity and location of P53 in cells and tissues.
Reliable research starts with reliable detection. Researchers can spend days preparing an experiment; if your antibody doesn’t work properly, you are losing money, samples and time. A validated TP53 gives you full confidence in the results of your project.
See how our TP53 antibody was tested and validated in WB, IHC, IF, and IP.
Learn more about our results:
abx159710 (p53) WB: successful, some background non-specific binding suggest further optimisation of WB protocol may be useful.
